Emerging Markets Earnings Roundup: GSK, AbbVie, Novo Nordisk (Part 5)
This article was originally published in PharmAsia News
Executive Summary
GSK reported that China pharmaceutical and vaccines sales were down 29% in Q4 and 18% for full year 2013, but CEO Andrew Witty tried to assure investors that sales are stabilizing. AbbVie chugs along on Humira and Novo Nordisk warns that emerging markets currency volatility may hit launch plans.
You may also be interested in...
Novo Nordisk CEO To Focus On U.S. As COO Schultz Gains Extra Duties
The sharing of executive responsibilities with Kare Schultz frees up CEO Lars Sorensen to focus on key growth markets, as Novo Nordisk faces growing competitive pressures from generics, new diabetes market entrants and a tougher pricing environment.
The Specter Of Spin-off Plans Dominates Pfizer Year-end Earnings
Although the company beat estimates and executed on an ambitious late-stage pipeline, analysts on Pfizer’s earnings call were focused on palbociclib, Prevnar, and the pharma’s plans for its established products business.
Novo Nordisk Dismayed By “Complete Response” Letter For Insulin Degludec
FDA is requesting data from a dedicated cardiovascular outcomes trial before approving the ultra-long-acting insulins Tresiba and Ryzodeg. News of the regulatory setback caused a 13% drop in the company’s stock price on Feb. 11.